Adagene Inc
ADAG1.820USD
-0.010-0.55%
收盘 12/19, 16:00（美东）报价延迟15分钟
107.22M总市值
亏损市盈率 TTM
关于 Adagene Inc 公司
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Adagene Inc简介
公司代码ADAG
公司名称Adagene Inc
上市日期Feb 09, 2021
CEOLuo (Peter)
员工数量138
证券类型Depository Receipt
年结日Feb 09
公司地址4F, Building C14, No. 218, Xinghu Street
城市SUZHOU
上市交易所NASDAQ OMX - NASDAQ BASIC
国家China
邮编- -
电话8651287773632
网址https://www.adagene.com/
公司代码ADAG
上市日期Feb 09, 2021
CEOLuo (Peter)
Adagene Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-3.45%
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Lefei Sun
Mr. Lefei Sun
Director
Director
--
--
Dr. Li Min, Ph.D.
Dr. Li Min, Ph.D.
Independent Director
Independent Director
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
Ms. Yuwen Liu
Ms. Yuwen Liu
Independent Director
Independent Director
--
--
Dr. Zheng Songmao
Dr. Zheng Songmao
Associate Vice President of Research and Development
Associate Vice President of Research and Development
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-3.45%
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Lefei Sun
Mr. Lefei Sun
Director
Director
--
--
Dr. Li Min, Ph.D.
Dr. Li Min, Ph.D.
Independent Director
Independent Director
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
收入明细
FY2024
FY2023
FY2022
FY2021
FY2020
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
China (Mainland)
103.20K
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月27日 周四
更新时间: 11月27日 周四
持股股东
股东类型
持股股东
持股股东
占比
General Atlantic LLC
8.03%
Olive Tree Capital
7.57%
WuXi AppTec Co, Ltd.
7.00%
Panacea Venture
4.77%
HSG Holding Ltd.
2.85%
其他
69.78%
持股股东
持股股东
占比
General Atlantic LLC
8.03%
Olive Tree Capital
7.57%
WuXi AppTec Co, Ltd.
7.00%
Panacea Venture
4.77%
HSG Holding Ltd.
2.85%
其他
69.78%
股东类型
持股股东
占比
Investment Advisor
13.29%
Venture Capital
12.37%
Private Equity
8.03%
Individual Investor
2.77%
Corporation
1.93%
Hedge Fund
0.35%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.02%
其他
61.08%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
34
16.13M
33.64%
--
2025Q3
35
16.13M
34.15%
+1.22M
2025Q2
33
14.91M
35.61%
-1.53M
2025Q1
31
16.44M
41.65%
-3.18M
2024Q4
29
17.99M
26.58%
+3.27M
2024Q3
27
14.73M
28.57%
+3.50M
2024Q2
28
11.22M
29.45%
-1.07M
2024Q1
30
12.30M
23.60%
+1.88M
2023Q4
27
7.12M
26.44%
-1.20M
2023Q3
33
8.32M
27.49%
-14.57K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
General Atlantic LLC
3.83M
8.12%
--
--
Jun 30, 2025
Olive Tree Capital
3.57M
7.57%
--
--
Feb 28, 2025
WuXi AppTec Co, Ltd.
3.98M
8.45%
--
--
Mar 31, 2025
HSG Holding Ltd.
1.34M
2.85%
--
--
Jun 30, 2025
Luo (Peter)
1.31M
2.77%
-46.66K
-3.45%
Feb 28, 2025
Impresa Management LLC
1.29M
2.74%
+1.29M
--
Feb 28, 2025
GP Healthcare Capital Co., Ltd.
910.00K
1.93%
+910.00K
--
Feb 28, 2025
Mill Creek Capital Advisors, LLC
199.61K
0.42%
--
--
Jun 30, 2025
Kamunting Street Capital Management, L.P.
126.03K
0.27%
+126.03K
--
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Adagene Inc的前五大股东是谁？
Adagene Inc 的前五大股东如下：
General Atlantic LLC持有股份：3.83M，占总股份比例：8.12%。
Olive Tree Capital持有股份：3.57M，占总股份比例：7.57%。
WuXi AppTec Co, Ltd.持有股份：3.98M，占总股份比例：8.45%。
HSG Holding Ltd.持有股份：1.34M，占总股份比例：2.85%。
Luo (Peter)持有股份：1.31M，占总股份比例：2.77%。
General Atlantic LLC持有股份：3.83M，占总股份比例：8.12%。
Olive Tree Capital持有股份：3.57M，占总股份比例：7.57%。
WuXi AppTec Co, Ltd.持有股份：3.98M，占总股份比例：8.45%。
HSG Holding Ltd.持有股份：1.34M，占总股份比例：2.85%。
Luo (Peter)持有股份：1.31M，占总股份比例：2.77%。
Adagene Inc的前三大股东类型是什么？
Adagene Inc 的前三大股东类型分别是：
General Atlantic LLC
Olive Tree Capital
WuXi AppTec Co, Ltd.
General Atlantic LLC
Olive Tree Capital
WuXi AppTec Co, Ltd.
有多少机构持有Adagene Inc(ADAG)的股份？
截至2025Q4，共有34家机构持有Adagene Inc的股份，合计持有的股份价值约为16.13M，占公司总股份的33.64%。与2025Q3相比，机构持股有所增加，增幅为-0.51%。
哪个业务部门对Adagene Inc的收入贡献最大？
在FY2024，--业务部门对Adagene Inc的收入贡献最大，创收--，占总收入的--%。
